Related Experiment Video
Updated: Jun 7, 2026
07:28
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
Published on: April 6, 2017
Budesonide/formoterol combination in COPD: a US perspective.
Amir Sharafkhaneh1, Amarbir S Mattewal, Vinu M Abraham
1Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA. amirs@bcm.tmc.edu
International Journal of Chronic Obstructive Pulmonary Disease
|November 2, 2010
Summary
This review examines the efficacy and safety of budesonide/formoterol for managing stable chronic obstructive pulmonary disease (COPD). The combination inhaler is approved in the US for maintenance therapy in COPD patients.
Area of Science:
- Pulmonology
- Pharmacology
Background:
- Chronic obstructive pulmonary disease (COPD) is a progressive lung disease primarily caused by smoking.
- It is characterized by airflow limitation, hyperinflation, and inflammation, leading to reduced quality of life.
Purpose of the Study:
- To review the efficacy and safety of budesonide/formoterol combination therapy for stable COPD.
- To evaluate the US FDA-approved pressurized metered dose inhaler formulation.
Main Methods:
- Review of available clinical data on budesonide/formoterol in COPD patients.
- Assessment of efficacy and safety profiles from published studies.
Main Results:
- Budesonide/formoterol combination therapy is available for stable COPD management.
- The US FDA approved a specific formulation for maintenance therapy.
Conclusions:
- Combination inhalers offer a therapeutic option for COPD management.
- Further evaluation of budesonide/formoterol efficacy and safety in COPD is warranted.
Related Concept Videos
01:26COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
01:23Inhaled Medications
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
01:29Chronic Obstructive Pulmonary Disease-V: Management
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
01:17Drugs Used in Lower Respiratory Disorders: Overview
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...